Smart Capital Traders
  • Politics
  • Investing
  • Latest News
  • Stocks

Smart Capital Traders

  • Politics
  • Investing
  • Latest News
  • Stocks
Politics

Dr. Oz becomes next head of Medicare and Medicaid Services following approval from full Senate

by admin April 4, 2025
April 4, 2025
Dr. Oz becomes next head of Medicare and Medicaid Services following approval from full Senate

Dr. Mehmet Oz will serve as the next administrator of the Centers for Medicare and Medicaid Services after the full Senate voted along party lines to confirm his nomination on Thursday. 

The former daytime TV doctor turned politician will be in charge of nearly $1.5 trillion in federal healthcare spending. His duties will entail overseeing Medicare, Medicaid and the Children’s Health Insurance Program (CHIP), including directing decisions related to how the government covers procedures, hospital stays and medication, as well as the reimbursement rates at which healthcare providers get paid for their services.   

Medicare is a federal healthcare program for seniors aged 65 and up, and currently provides coverage to about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, a public health assistance program for people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov. Meanwhile, CHIP, which provides free or low-cost health coverage for eligible low-income children and family members, assists around 7.2 million individuals. 

A graduate of Harvard University, Oz received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime television, including ‘The Oprah Winfrey Show,’ and 13 seasons of ‘The Dr. Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He lost to John Fetterman, then the state’s lieutenant governor.

‘Dr. Oz has a strong desire to modernize CMS and encourage healthy lifestyles for all Americans, including by focusing on the underlying causes of chronic disease and implementing innovative technologies,’ Senate Finance Committee Chairman Sen. Mike Crapo, R-Idaho, said Thursday.

Crapo, who led Oz’s nomination process at the committee level, commended Oz for his ‘diligence and accessibility’ throughout the process, including his willingness to answer ‘hundreds’ of questions for the record.

Those questions came from both Republicans and Democrats. They included asking about Oz’s stance on abortion, transgender medical treatments, Medicare privatization, prescription drug pricing and more. Potential financial conflicts of interest were also a concern among Democratic lawmakers throughout Oz’s confirmation process. Oz has committed to divesting any holdings that may pose an issue. 

Thursday’s confirmation comes as the Trump administration continues to work to finalize the rest of its political appointments, including notably the president’s pick to be the next United Nations ambassador and his pick for director of the Consumer Financial Protection Bureau. 

Per The Washington Post’s ‘political appointee tracker,’ there are currently still 233 nominees being considered by the Senate.

This post appeared first on FOX NEWS

previous post
Waltz’s Signal chat woes snowball as Trump admin defends national security advisor
next post
Bitcoin Holds Up, but Remains Short of Relative Breakout

related articles

Drag shows, Arabic Sesame Street, lonely rats: GOP...

December 24, 2024

One Republican senator voted against confirming Trump nominee...

April 4, 2025

Who is Pierre Poilievre? Canada’s Conservative leader seeking...

January 7, 2025

GOP rebels head to White House for meeting...

March 5, 2025

Don’t blame your health insurance company for your...

December 29, 2024

Trump administration prevails as appeals court pauses lower...

June 11, 2025

Ukraine launches biggest drone attack on Moscow, killing...

March 11, 2025

Pete Hegseth may release sexual assault accuser from...

December 18, 2024

Waltz tells Iran to give up nuclear program...

March 24, 2025

Top Trump ally predicts Senate will blow past...

June 19, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Most Popular

    • 1

      Retraction of Forecast Financial Information Plus Announcement on New Metallurgical Testwork Results

      October 15, 2024
    • 2

      Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions

      October 19, 2024
    • 3

      As North Korea, Iran and China support Russia’s war, is a ‘new axis’ emerging?

      October 25, 2024
    • 4

      Lode Gold Launches Exploration Program at One of the Largest Land Packages in New Brunswick

      October 19, 2024
    • 5

      Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

      October 31, 2024

    Categories

    • Investing (1,916)
    • Latest News (2,256)
    • Politics (2,372)
    • Stocks (790)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smartcapitaltraders.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smartcapitaltraders.com | All Rights Reserved